Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
71
GLSI Quote, Financials, Valuation and Earnings
Last price:
$12.93
Seasonality move
:
-2.66%
Day range:
$11.95 - $13.10
52-week range:
$7.78 - $14.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
82.50x
Volume:
333K
Avg. volume:
252K
1-year change:
3.91%
Market cap:
$180.2M
Revenue:
--
EPS (TTM):
-$1.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -- | -- | -- | $45.00 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GLSI
Greenwich LifeSciences, Inc.
|
$13.01 | $45.00 | $180.2M | -- | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$4.91 | $42.50 | $14.9M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.30 | $0.85 | $667.9M | 8.90x | $0.80 | 0% | 10.30x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.73 | $11.00 | $139.1M | 24.89x | $0.00 | 0% | 2.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | 1.626 | -- | 2.35x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -$4.2M | -781.94% | -781.94% | -- | -$2.7M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Greenwich LifeSciences, Inc. vs. Competitors
-
Which has Higher Returns GLSI or AIM?
AIM ImmunoTech has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -10571.43%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About GLSI or AIM?
Greenwich LifeSciences, Inc. has a consensus price target of $45.00, signalling upside risk potential of 245.89%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Greenwich LifeSciences, Inc., analysts believe AIM ImmunoTech is more attractive than Greenwich LifeSciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.1 0 0 AIMAIM ImmunoTech1 0 0 -
Is GLSI or AIM More Risky?
Greenwich LifeSciences, Inc. has a beta of 2.924, which suggesting that the stock is 192.436% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock GLSI or AIM?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLSI or AIM?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns GLSI or CVM?
CEL-SCI Corp. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of --. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About GLSI or CVM?
Greenwich LifeSciences, Inc. has a consensus price target of $45.00, signalling upside risk potential of 245.89%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe CEL-SCI Corp. is more attractive than Greenwich LifeSciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.1 0 0 CVMCEL-SCI Corp.1 0 0 -
Is GLSI or CVM More Risky?
Greenwich LifeSciences, Inc. has a beta of 2.924, which suggesting that the stock is 192.436% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock GLSI or CVM?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLSI or CVM?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Greenwich LifeSciences, Inc.'s net income of -$4.2M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns GLSI or IGC?
IGC Pharma, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -953.4%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About GLSI or IGC?
Greenwich LifeSciences, Inc. has a consensus price target of $45.00, signalling upside risk potential of 245.89%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma, Inc. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe IGC Pharma, Inc. is more attractive than Greenwich LifeSciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.1 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is GLSI or IGC More Risky?
Greenwich LifeSciences, Inc. has a beta of 2.924, which suggesting that the stock is 192.436% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock GLSI or IGC?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLSI or IGC?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
-
Which has Higher Returns GLSI or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -255.85%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About GLSI or NBY?
Greenwich LifeSciences, Inc. has a consensus price target of $45.00, signalling upside risk potential of 245.89%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Greenwich LifeSciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Greenwich LifeSciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is GLSI or NBY More Risky?
Greenwich LifeSciences, Inc. has a beta of 2.924, which suggesting that the stock is 192.436% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock GLSI or NBY?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLSI or NBY?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M NBYNovaBay Pharmaceuticals, Inc.10.30x 8.90x $521K -$1.3M
-
Which has Higher Returns GLSI or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of 13.19%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About GLSI or PLX?
Greenwich LifeSciences, Inc. has a consensus price target of $45.00, signalling upside risk potential of 245.89%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Greenwich LifeSciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.1 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is GLSI or PLX More Risky?
Greenwich LifeSciences, Inc. has a beta of 2.924, which suggesting that the stock is 192.436% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock GLSI or PLX?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLSI or PLX?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M PLXProtalix Biotherapeutics, Inc.2.20x 24.89x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
